Amsterdam, The Netherlands - September 18, 2008 - Amsterdam Molecular
Therapeutics (Euronext: AMT),  a leader  in the field  of human  gene
therapy, today announced that it obtained a license from Amgen to use
their GDNF gene for the development  of a gene therapy treatment  for
Parkinson's  disease.  The  combination  of  this  gene  with   AMT's
proprietary adeno-associated virus (AAV) gene therapy platform  could
potentially  allow  the  development   of  an  effective,   long-term
treatment for this progressive and crippling disease.

Parkinson's disease  is  the  second  most  common  neurodegenerative
disease. It usually affects people over 65 with an estimated total of
4.5 million patients worldwide. Due to increasing life expectancy  of
the general  population,  the  number of  patients  with  Parkinson's
disease is expected to  double to around  9 million patients  between
now and the year 2030.

Patients with  Parkinson's  disease  slowly  lose  control  of  their
muscles, resulting in tremors,  stiffness, slowness of movement,  and
lack of coordination and thus in  a serious loss of quality of  life.
Parkinson's is caused by degeneration and  death of nerve cells in  a
specific part of the brain. These cells produce dopamine, a substance
necessary for  communication  between  nerve cells  involved  in  the
coordination of movement. Current therapies are limited to  treatment
of symptoms. There are no therapies available that slow down or  halt
the progression of the disease.

A new way to deliver the GDNF gene
 "This license from Amgen offers  us a unique opportunity to  combine
our gene technology  and know-how  with the GDNF  gene as  a tool  to
create a potential breakthrough in the treatment for this common  and
severely debilitating disease," said Ronald  Lorijn, CEO of AMT   "We
believe our  gene  therapy approach  could  be an  effective  way  to
deliver the gene to the regions of the brain affected by  Parkinson's
disease."

Protect and improve nerve cells with GDNF
The GDNF gene contains  the information for  a protein necessary  for
the development and survival  of nerve cells.  AMT will combine  this
gene with its own  proprietary technology to  develop a gene  therapy
treatment that aims to protect and enhance the function of the  nerve
cells that produce  dopamine. The  positive effect of  GDNF on  nerve
cells has  been  shown  in  several  animal  studies,  making  it  an
attractive candidate for the  treatment of Parkinson's disease..  AMT
believes that its  gene-delivery platform may  potentially provide  a
solution for delivering GDNF to the brain.

About Amsterdam Molecular Therapeutics
AMT has  a unique  gene  therapy platform  that  to date  appears  to
circumvent many if not all of the obstacles that have prevented  gene
therapy  from  becoming  a  mainstay  of  clinical  medicine.   Using
adeno-associated viral  (AAV)  vectors  as the  delivery  vehicle  of
choice for therapeutic genes, the company has been able to design and
validate  what  is  probably  the  first  stable  and  scalable   AAV
production  platform.  As  such,  AMT's  proprietary  platform  holds
tremendous  promise  for   thousands  of   rare  (orphan)   diseases,
especially the ones that are caused by one faulty gene. AMT currently
has a product  pipeline with  seven products at  different stages  of
development.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology  pioneer since 1980,  Amgen was one  of
the first companies to realize the new science's promise by  bringing
safe and effective  medicines from  lab, to  manufacturing plant,  to
patient. Amgen therapeutics  have changed the  practice of  medicine,
helping millions  of people  around the  world in  the fight  against
cancer, kidney  disease,  rheumatoid  arthritis,  and  other  serious
illnesses. With a deep and broad pipeline of potential new medicines,
Amgen remains committed to advancing science to dramatically  improve
people's lives. To learn  more about our  pioneering science and  our
vital medicines, visit www.amgen.com.
For information

André Verwei                       Rob Janssen
CFO                                Director Corporate Communications
                                   & Investor Relations
+31 20 566 5686                    +31 20 566 7509
a.verwei@amtbiopharma.com          r.janssen@amtbiopharma.com
www.amtbiopharma.com


Certain  statements  in  this  press  release  are   "forward-looking
statements" including  those that  refer  to management's  plans  and
expectations  for   future   operations,  prospects   and   financial
condition.   Words   such   as   "strategy,"   "expects,"    "plans,"
"anticipates,"   "believes,"   "will,"   "continues,"    "estimates,"
"intends," "projects," "goals," "targets" and other words of  similar
meaning are  intended to  identify such  forward-looking  statements.
Such  statements  are  based  on  the  current  expectations  of  the
management of Amsterdam Molecular  Therapeutics only. Undue  reliance
should not be placed  on these statements  because, by their  nature,
they are subject to  known and unknown risks  and can be affected  by
factors that  are beyond  the control  of AMT.  Actual results  could
differ materially  from  current  expectations due  to  a  number  of
factors and uncertainties  affecting AMT's  business, including,  but
not limited to, the timely commencement and success of AMT's clinical
trials and research endeavors, delays in receiving U.S. Food and Drug
Administration or  other  regulatory  approvals  (i.e.  EMEA,  Health
Canada), market acceptance of AMT's products, effectiveness of  AMT's
marketing and  sales  efforts,  development  of  competing  therapies
and/or technologies, the terms of any future strategic alliances, the
need for  additional  capital,  the inability  to  obtain,  or  meet,
conditions imposed for required governmental and regulatory approvals
and consents. AMT  expressly disclaims  any intent  or obligation  to
update these forward-looking  statements except as  required by  law.
For a more detailed description of the risk factors and uncertainties
affecting AMT,  refer  to  the prospectus  of  AMT's  initial  public
offering on June 20, 2007,  and AMT's public announcements made  from
time to time.


http://hugin.info/139313/R/1252487/272497.pdf


Copyright © Hugin AS 2008. All rights reserved.